Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inventiva S.A. ADR (IVA)

Inventiva S.A. ADR (IVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 602,778
  • Shares Outstanding, K 145,951
  • Annual Sales, $ 15,930 K
  • Annual Income, $ -199,340 K
  • EBIT $ 0 M
  • EBITDA $ -100 M
  • 60-Month Beta 0.74
  • Price/Sales 61.29
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.29
  • Number of Estimates 1
  • High Estimate -0.29
  • Low Estimate -0.29
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.55 +16.34%
on 11/13/25
4.63 -10.80%
on 11/26/25
+0.03 (+0.73%)
since 11/05/25
3-Month
3.55 +16.34%
on 11/13/25
7.98 -48.26%
on 10/28/25
-1.44 (-25.85%)
since 09/05/25
52-Week
2.11 +95.62%
on 01/14/25
7.98 -48.26%
on 10/28/25
+1.49 (+56.40%)
since 12/05/24

Most Recent Stories

More News
Inventiva Launches $100 Million ATM Program to Boost R&D Efforts

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Inventiva...

IVA : 4.13 (-1.20%)
Inventiva (IVA) Receives a Buy from Piper Sandler

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Inventiva, with a price target of $26.00. The company’s shares closed yesterday at $5.53.Elevate Your Investing...

IVA : 4.13 (-1.20%)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Quest Diagnostics (DGX) and Inventiva (IVA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quest Diagnostics (DGX – Research Report) and Inventiva (IVA – Research Report).Elevate Your Investing Strategy: Take...

DGX : 182.51 (-0.91%)
IVA : 4.13 (-1.20%)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: PepGen Inc. (PEPG) and Inventiva (IVA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on PepGen Inc. (PEPG – Research Report) and Inventiva (IVA – Research Report).Elevate Your Investing Strategy: Take advantage...

IVA : 4.13 (-1.20%)
PEPG : 5.44 (+2.45%)
Canaccord Genuity Sticks to Their Buy Rating for Inventiva (IVA)

In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva, with a price target of $20.00. The company’s shares closed yesterday at $6.24.Elevate Your Investing...

IVA : 4.13 (-1.20%)
Canaccord Genuity Reaffirms Their Buy Rating on Inventiva (IVA)

In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva, with a price target of $20.00. The company’s shares closed yesterday at $5.91.Elevate Your Investing...

IVA : 4.13 (-1.20%)
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

VKTX : 38.55 (-0.05%)
GALT : 5.74 (-8.89%)
ETNB : 14.84 (unch)
IVA : 4.13 (-1.20%)
NVO : 47.86 (-0.27%)
MDGL : 577.30 (-1.52%)
TERN : 29.36 (+8.22%)
GLMD : 1.1200 (-0.88%)
SGMT : 6.39 (+0.63%)
IQV : 225.85 (+0.41%)
Inventiva Reports 2022 First-Half Financial Information¹

Cash position2 at €87.2 m as of June 30, 2022Revenues of €0.1 m in H1 2022Inventiva entered into a finance loan and a warrant agreement for up to €50...

IVA : 4.13 (-1.20%)
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Daix (France), Long Island City (New York, United States), July 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical...

IVA : 4.13 (-1.20%)
Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D

The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin...

IVA : 4.13 (-1.20%)

Business Summary

Inventiva S.A. is a clinical-stage biopharmaceutical company. It is focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Inventiva S.A. is based in Daix, France.

See More

Key Turning Points

3rd Resistance Point 4.37
2nd Resistance Point 4.29
1st Resistance Point 4.21
Last Price 4.13
1st Support Level 4.05
2nd Support Level 3.97
3rd Support Level 3.89

See More

52-Week High 7.98
Fibonacci 61.8% 5.74
Fibonacci 50% 5.05
Fibonacci 38.2% 4.35
Last Price 4.13
52-Week Low 2.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar